Document is current
Any future updates will be listed below
-
Authors
Abellan-Perpiñan, Jose-Maria
Redondo Margüello, Esther
Gil de Miguel, Ángel
Sanz Muñoz, Iván
Diaz-Aguiló, Ariadna
Palomo, Paloma
Farré, Manel
Callejo, Daniel
Pinel, Marco
López-Belmonte, Juan Luis
-
Funding
Funding for this research was provided by:
Sanofi España
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 8 January 2026
First Online: 4 March 2026
Declarations
:
: This study does not involve real patients; instead, it is based on a simulated cohort of patients. Therefore, ethical approval and informed consent are not applicable.
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jose-Maria Abellan-Perpiñan has been compensated by Sanofi for participating in advisory groups and has received funding from Novartis to conduct a study over the last year. Esther Redondo Margüello has participated in advisory boards, conferences, courses and lectures organized by Sanofi, MSD, GSK, Seqirus, AstraZeneca, Takeda and, Pfizer. Ángel Gil de Miguel has received support from Sanofi in recent years for attendance at meetings and congresses, as well as payment for papers and participation in advisory groups. Iván Sanz Muñoz has participated in advisory boards and conferences organized by Sanofi. Ariadna Diaz-Aguiló, Paloma Palomo, Manel Farré and Juan Luis López-Belmonte are employees of Sanofi. Daniel Callejo and Marco Pinel are employees of IQVIA consulting, which received funding from Sanofi to conduct the analysis.
